Investing.com - Mesoblast (NASDAQ:MESO) reported on Friday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.219 on revenue of $2.24M. Analysts polled by Investing.com anticipated EPS of $-0.1043 on revenue of $21.85M.
Mesoblast shares are down 0% from the beginning of the year, still down 54.76% from its 52 week high of $21.22 set on August 17, 2020. They are under-performing the Euro Stoxx 50 which is up 2.82% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings missed by Roche Holding ADR on February 1, who reported EPS of $1.21 on revenue of $15.88B, compared to forecasts EPS of $1.28 on revenue of $16.45B.
Eli Lilly had beat expectations on January 29 with fourth quarter EPS of $2.75 on revenue of $7.44B, compared to forecast for EPS of $2.37 on revenue of $7.27B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar